Mechanisms of Suanzaoren () and its processed products in treating insomnia: an integrated study based on network
Zhang Yuan1, Cheng Shizan1, Hua Yue1
1Office of Traditional Chinese Medicine Processing, Liaoning University of Traditional Chinese Medicine, Dalian 100600, China.
Objective:
To elucidate the potential mechanisms and identify bioactive components of Suanzaoren (Ziziphi Spinosae Semen) (ZSS) and it's processed products for insomnia treatment.
Methods:
The principal components of ZSS and its processed products were analyzed using Ultra-Performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS). The effects of ZSS on insomnia were assessed in para-chlorophenylalanine (PCPA)-induced rats. Additionally, to investigate the mechanisms of action in insomnia, serum and hippocampal non-targeted metabolomics were performed alongside network pharmacology and molecular docking.
Results:
UPLC-Q-TOF-MS was used to analyze the main components of ZSS and its processed products. In the insomnia rat model induced by PCPA, both ZSS and its processed products demonstrated therapeutic effects, with the processed products showing particularly significant effects, significantly increasing the levels of the Gamma-Aminobutyric Acid and melatonin. Non-targeted metabolomics identified 23 and 10 potential differential metabolites in serum and hippocampus, respectively, involving pathways such as lipid metabolism and amino acid metabolism. Network pharmacology identified three core targets, mainly associated with pathways such as Transient Receptor Potential channel regulation, Advanced Glycation End-products-Receptor for Advanced Glycation End-products signaling pathway, and neuroactive ligand-receptor interaction. Molecular docking confirmed that the main active components of ZSS can stably bind to these core targets, thereby exerting an effect in improving insomnia.
Conclusions:
Combining in vivo experiments, metabolomics, and network pharmacology, we have identified potential pharmacological mechanisms by which ZSS and its derivatives mitigate insomnia. These findings provide a theoretical foundation for the further development and utilization of ZSS, supporting the innovation of new therapeutic agents for insomnia treatment.
More Related Videos
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:19Management of Insomnia
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:23Antidepressant Drugs: MAOIs and Other Agents
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:14CNS Depressants: Barbiturates and Benzodiazepines